http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Fibrocell Reports Second Quarter 2019 Financial Results and Recent Operational Highlights
-
Fibrocell to Present at BIO International Convention 2019
-
Fibrocell to Present at BIO International Convention 2019
-
Fibrocell Science (FCSC) Granted FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for Treatment of RDEB
-
Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB
-
Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB
-
Fibrocell Reports First Quarter 2019 Financial Results and Recent Operational Highlights
-
Fibrocell Reports First Quarter 2019 Financial Results and Recent Operational Highlights
-
Fibrocell to Host Conference Call and Webcast on Wednesday, May 15, 2019 to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights
-
Fibrocell to Host Conference Call and Webcast on Wednesday, May 15, 2019 to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights
-
Fibrocell Science (FCSC) Announces Pact with Castle Creek Pharma to Develop and Commercialize FCX-007 Gene Therapy
-
Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy
-
Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy
-
Fibrocell Announces Board Member Christine St.Clare Honored by National Association of Corporate Directors
-
Fibrocell Announces Board Member Christine St.Clare Honored by National Association of Corporate Directors
-
Fibrocell Science (FCSC) Reports Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007
-
Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007
-
Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007
-
Fibrocell to Host Conference Call & Webcast for Full Year 2018 Financial Results and Recent Highlights on March 27, 2019
-
Fibrocell to Host Conference Call & Webcast for Full Year 2018 Financial Results and Recent Highlights on March 27, 2019
-
Fibrocell to Present at 21st Annual BIO CEO & Investor Conference
-
Fibrocell to Present at 21st Annual BIO CEO & Investor Conference
-
Fibrocell to Present at Phacilitate Leaders World 2019
-
Fibrocell to Present at Phacilitate Leaders World 2019
-
Fibrocell Receives $900,000 Investment from EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation
-
Fibrocell Receives $900,000 Investment from EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation
-
Fibrocell Reports Third Quarter 2018 Financial Results and Recent Highlights
-
Fibrocell Reports Third Quarter 2018 Financial Results and Recent Highlights
-
Intrexon Announces Third Quarter 2018 Financial Results
-
Fibrocell to Host Conference Call and Webcast on Tuesday, November 13, 2018 to Discuss Third Quarter 2018 Financial Results and Recent Highlights
-
Fibrocell to Host Conference Call and Webcast on Tuesday, November 13, 2018 to Discuss Third Quarter 2018 Financial Results and Recent Highlights
-
Fibrocell Science (FCSC) Receives FDA Guidance on Phase 3 Clinical Trial Design for FCX-007
-
Fibrocell Receives Guidance from FDA on Phase 3 Clinical Trial Design for FCX-007
-
Fibrocell Receives Guidance from FDA on Phase 3 Clinical Trial Design for FCX-007
-
Fibrocell to Present at Upcoming Industry and Investor Conferences
-
Fibrocell to Present at Upcoming Industry and Investor Conferences
-
Fibrocell Science (FCSC) Secures $1.4M FDA Orphan Grant for FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
-
Fibrocell Awarded $1.4 Million FDA Orphan Grant for FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
-
Fibrocell Awarded $1.4 Million FDA Orphan Grant for FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
-
Fibrocell Science (FCSC) Reports FDA Fast Track Designation of FCX-013 for Treatment of Moderate to Severe Localized Scleroderma
-
Fibrocell Announces FDA Fast Track Designation of FCX-013 for Treatment of Moderate to Severe Localized Scleroderma
-
Fibrocell Announces FDA Fast Track Designation of FCX-013 for Treatment of Moderate to Severe Localized Scleroderma
-
Fibrocell to Present at 20th Annual Rodman & Renshaw Global Investment Conference
-
Fibrocell to Present at 20th Annual Rodman & Renshaw Global Investment Conference
-
Intrexon Business Update and Conference Call
-
Fibrocell Reports Second Quarter 2018 Financial Results and Recent Highlights
-
Fibrocell Reports Second Quarter 2018 Financial Results and Recent Highlights
-
Fibrocell to Host Conference Call and Webcast on Thursday, August 9, 2018 to Discuss Second Quarter 2018 Financial Results and Recent Highlights
-
Fibrocell to Host Conference Call and Webcast on Thursday, August 9, 2018 to Discuss Second Quarter 2018 Financial Results and Recent Highlights
-
Fibrocell Science (FCSC) Prices 2.04M Share Common Offering at $2.85/Sh

